WallStSmart
THRD

Third Harmonic Bio Inc.

NASDAQ: THRD · HEALTHCARE · BIOTECHNOLOGY

$5.38
+0.00% today

Updated 2026-10-28

Market cap
$242.79M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.24
Dividend yield
—
52W range
$0 – $0
Volume
—

Third Harmonic Bio Inc. (THRD) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20202021202220232024
Revenue$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)—————
Cost of revenue——$38000.00$35000.00$49000.00
Gross profit——$-38000.00$-35000.00$-49000.00
Gross margin—————
R&D$9.95M$15.75M$24.41M$23.96M$36.50M
SG&A$1.17M$3.26M$13.30M$19.99M$22.37M
Operating income$-11.12M$-19.00M$-37.71M$-43.95M$58.87M
Operating margin—————
EBITDA$-1.69M$-29.61M$-40.26M$-30.79M$-45.42M
EBITDA margin—————
EBIT$-12.81M$-19.00M$-37.71M$-30.82M$-45.47M
Interest expense—$10.61M$2.55M——
Income tax—————
Effective tax rate0.0%0.0%0.0%0.0%0.0%
Net income$-12.81M$-29.61M$-37.71M$-30.82M$45.47M
Net income growth (YoY)—-131.2%-27.4%+18.3%+247.5%
Profit margin—————

Frequently asked questions

How much free cash flow does THRD generate?

THRD produced $-34.51M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is THRD's balance sheet healthy?

THRD holds $285.06M in cash and equivalents against — in long-term debt, on $285.15M of shareholder equity. That debt is best read against the cash flow the business throws off each year.